Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI

Study Overview
=================
Brief Summary
-----------------
Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet activity in patients undergoing primary PCI. Methods: sixty patients were recruited in this study. Patients were allocated to one of four groups according to the diabetes and smoking status. Non smokers- non diabetic patients, smokers non diabetic patients, non smokers diabetic patients, and smokers diabetic patients, 15 patients in each group. All patients received 180 mg ticagrelor before PCI. Platelet reactivity index(PRI) and maximum platelet aggregation were measured 24 hours after ticagrelor loading dose for each patient as indicators for antiplatelet efficacy. PRI and/or MPA values > 50% were defined as high platelet reactivity.

Official Title
-----------------
Ndividualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI

Conditions
-----------------
Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention

Intervention / Treatment
-----------------
* Drug: Ticagrelor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute coronary syndrome (ACS) undergoing PCI Exclusion Criteria: Patients who had a history of severe bleeding, serious bleeding tendency, history of intracranial hemorrhage, signs of active bleeding, thrombocytopenia, uncontrolled hypertension, hypersensitivity to the used drugs (clopidogrel or ticagrelor), concomitant use of strong CYP inducers or inhibitors, and/or severe liver disorders were excluded from the study. Patients with previous history of coronary artery disease, previous PCI or patients administering other antiplatelets were excluded from the current study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non smokers- non diabetic patients<br> | Drug: Ticagrelor<br>* Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI<br>* Other names: Primary percutaneous coronary intervention (PCI);|
| smokers non diabetic patients<br> | Drug: Ticagrelor<br>* Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI<br>* Other names: Primary percutaneous coronary intervention (PCI);|
| non smokers diabetic patients<br> | Drug: Ticagrelor<br>* Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI<br>* Other names: Primary percutaneous coronary intervention (PCI);|
| smokers diabetic patients<br> | Drug: Ticagrelor<br>* Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI<br>* Other names: Primary percutaneous coronary intervention (PCI);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet Reactivity Index and maximum platelet aggregation | Platelet aggregation indicator | 24 hours after PCI |